TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12175402
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection into the periprostatic nerve plexus
Study: 28394933
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg+40 mg)
Study: 11094106
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of rizatriptan for three attacks and placebo for one attack
Study: 8382710
Drug: Clomipramine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine and maprotiline treatment
Study: 3786347
Drug: 0.695 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.695 g/kg ethanol
Study: 6814355
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of cefuroxime
Study: 6814355
Drug: 4.8 x
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 x 10(6) U of aqueous procaine penicillin G intramuscularly and 1.0 g of probenecid
Study: 27436274
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes therapy
Study: 27436274
Drug: Conventional diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetes therapy
Study: 28507269
Drug: r‐tPA+low‐dose argatroban
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐tPA+low‐dose argatroban (100 μg/kg bolus followed by infusion of 1 μg/kg per minute for 48 hours)
Study: 28507269
Drug: r‐tPA+high‐dose argatroban
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐tPA+high‐dose argatroban (100 μg/kg bolus followed by infusion of 3 μg/kg per minute for 48 hours)
Study: 28507269
Drug: r‐tPA+low‐dose or
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐tPA+low‐dose or high‐dose argatroban
Study: 28507269
Drug: r‐tPA+low‐dose argatroban
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐tPA+low‐dose argatroban
Study: 28507269
Drug: r‐tPA+high‐dose argatroban
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐tPA+high‐dose argatroban
Study: 25891339
Drug: Heparin-lidocaine combination
Normalized name: heparin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-lidocaine combination
Study: 9246979
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of contraceptive pills
Study: 7906700
Drug: Contrast condition
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast condition (CC)
Study: 27026043
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day) + Interferon β-1a (30 μg/week)
Study: 27026043
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Interferon β-1a 30 μg/week)
Study: 24325987
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate 40 mg with lidocaine 1% (total volume 1 ml)
Study: 15726658
Drug: Placebo (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (IV and oral)
Study: 12657843
Drug: Conservative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative fluid management (1 ml/kg/h during surgery, total 9.5 ml/kg/h)
Study: 12657843
Drug: Aggressive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fluid management (8 ml/kg/h during surgery)
Study: 6384617
Drug: Corinfar (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corinfar (40 mg daily)
Study: 6384617
Drug: Isoptin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoptin (240 mg daily)
Study: 30747547
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (800 μg every 4 hours, three doses)
Study: 30747547
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (800 μg every 4 hours, three doses)
Study: 26091686
Drug: 80 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp with 30 mL of 270 mg I/mL contrast material and iterative reconstruction (IR)
Study: 26091686
Drug: 100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp with 60 mL of 370 mg I/mL contrast material and filtered back projection
Study: 22777367
Drug: Uterosacral vault
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral vault suspension with pelvic floor muscle training
Study: 22777367
Drug: Uterosacral vault
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral vault suspension without pelvic floor muscle training
Study: 12010583
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g/d, 3 g EPA+DHA)
Study: 12010583
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (placebo, 6 g/d)
Study: 9536924
Drug: Intravenous lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lactate
Study: 8587284
Drug: H.E.L.P. system
Approvals — FDA: no, EMA: no, PMDA: no
Description: H.E.L.P. system
Study: 31603121
Drug: Yoga +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga + standard antiemetic therapy
Study: 23987791
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic therapy alone
Study: 23095710
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg•kg(‐1)
Study: 21764136
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.7 mg (n = 341)
Study: 21764136
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.35 mg (n = 412)
Study: 12412825
Drug: Tilidine 50
Normalized name: tilidine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine 50 mg intravenously
Study: 12412825
Drug: Tilidine 50
Normalized name: tilidine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine 50 mg orally
Study: 12412825
Drug: Nortilidine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortilidine 10 mg intravenously
Study: 9584558
Drug: Anti-emetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-emetic therapy
Study: 3327931
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg twice daily)
Study: 183790
Drug: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S) at a dosage of 0.5 mg
Study: 17926610
Drug: New Bian-stone
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Bian-stone therapy
Study: 18082208
Drug: Daily cotrimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cotrimoxazole
Study: 1489026
Drug: Extradural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural infusion of lignocaine 0.75% after an initial dose of 10 ml of lignocaine 1.5%
Study: 1489026
Drug: Extradural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural infusion of bupivacaine 0.125% after an initial dose of 10 ml of bupivacaine 0.25%
Study: 30536638
Drug: Golimumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (subcutaneous administration)
Study: 27865117
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intraaortic balloon pump therapy)
Study: 27222510
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine
Study: 8485067
Drug: Nicorandil 20
Normalized name: nicorandil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 20 mg bid
Study: 15618027
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg bid
Study: 15618027
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg bid
Study: 8590781
Drug: Structured teaching/treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured teaching/treatment programme
Study: 28947022
Drug: FF/UMEC (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC (all doses)
Study: 20057195
Drug: Combined DAK
Normalized name: Di-Dak-Sol
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DAK therapy for obesity (inpatient therapy for 6 weeks followed by home-based outpatient treatment for 10.5 months)
Study: 20057195
Drug: Combined DAK
Normalized name: Di-Dak-Sol
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DAK therapy for obesity
Study: 17413047
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg daily for up to 14 days)
Study: 12845405
Drug: METH (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH (10 mg)
Study: 8875970
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitors
Study: 8445848
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 4.97 +/- 1.12 mg/kg (total dosage per exacerbation: 74.55 mg/kg)
Study: 8445848
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 9.60 +/- 2.70 mg/kg (total dosage per exacerbation: 165.12 mg/kg)
Study: 29336896
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 0.3 mg ranibizumab and TRP
Study: 29336896
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 0.3 mg ranibizumab
Study: 10753434
Drug: Various medical
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various medical treatments (central vasodilators, vestibular suppressants, calcium channel blockers, anticholinergic drugs, anticonvulsant drugs, gingko biloba)
Study: 25881589
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment for 10 days followed by esomeprazole 20 mg bid for 46 days
Study: 25881589
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg bid therapy for 8 weeks (control group)
Study: 9560861
Drug: Collaborative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care (enhanced management of pharmacotherapy and brief psychoeducational interventions)
Study: 8175505
Drug: Dipyridamole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.5 mg/kg)
Study: 29496472
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg once per day
Study: 20171409
Drug: Active patch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patch containing 10% methyl salicylate and 3% l-menthol
Study: 17384176
Drug: Low-dose deflazacort
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose deflazacort (DFZ) 7.5 mg for 6 months, followed by methyl prednisolone (MP) 4 mg for 6 months.
Study: 17384176
Drug: Methyl prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl prednisolone (MP) 4 mg for 6 months, followed by low-dose deflazacort (DFZ) 7.5 mg for 6 months.
Study: 14971531
Drug: Tramadol SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol SR 100 mg
Study: 202141
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg)
Study: 1634645
Drug: Chlorthalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (50 mg)
Study: 11736880
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg)
Study: 1634645
Drug: Atenolol and
Normalized name: atenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol and Chlorthalidone combination (100 mg and 50 mg)
Study: 31204832
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy modified for stalking offenders (DBT-S)
Study: 27861708
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 100,000 IU monthly
Study: 27861708
Drug: Standard-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vitamin D (placebo or 12,000 IU)
Study: 20166442
Drug: Single-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rosuvastatin 5 mg
Study: 20166442
Drug: Single-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rosuvastatin 10 mg
Study: 20166442
Drug: Single-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rosuvastatin 20 mg
Study: 20166442
Drug: Multiple-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose rosuvastatin 5 mg
Study: 20166442
Drug: Multiple-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose rosuvastatin 10 mg
Study: 20166442
Drug: Multiple-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose rosuvastatin 20 mg
Study: 15598476
Drug: Fluvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin + Fenofibrate combination therapy
Study: 9223543
Drug: Intrathecal neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal neostigmine + Intravenous alfentanil
Study: 16321619
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil
Study: 7516376
Drug: Terazosin, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin, dosage not specified, administered once daily.
Study: 7516376
Drug: Terazosin, long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin, long-term treatment for more than two years.
Study: 3953352
Drug: Intravenous lorcainide
Normalized name: lorcainide
DrugBank: Lorcainide (DB13653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lorcainide (2 mg/kg bolus at 2 mg/min followed by 0.14 mg/min or 200 mg/24 hours)
Study: 3953352
Drug: Oral lorcainide
Normalized name: tocainide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lorcainide (100 mg orally every 8 hours)
Study: 30182192
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT) using the first-generation BAT device
Study: 30182192
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT) using the Barostim Neo system
Study: 26381036
Drug: Intra-abdominal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-abdominal lavage with gentamicin-clindamycin solution (Group 2)
Study: 19769631
Drug: Medium-dose UVA1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UVA1
Study: 9656312
Drug: Physioacoustic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physioacoustic treatment group
Study: 2667779
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo and halothane by inhalation
Study: 2667779
Drug: Nalbuphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.1 mg.kg‐1 IV as premedication and isoflurane by inhalation
Study: 6608052
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (coronary bypass surgery)
Study: 29080265
Drug: Autologous cord
Normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cord blood (ACB) infusion
Study: 26044471
Drug: Scheimpflug noncontact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheimpflug noncontact tonometry with daily disposable hydrogel contact lenses (Dailies-nelfilcon A)
Study: 11097131
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) infusion (mean dose 2.4 +/- 0.9 mg/h), n = 33
Study: 26671958
Drug: Ebola vaccine
Normalized name: ebola vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola vaccine efficacy trial starting after 1 August
Study: 10743981
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin 70/30
Study: 14624083
Drug: Active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intervention (frequent active cervical rotation, assessment and treatment according to McKenzie's principles)
Study: 10844834
Drug: Rocuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium infusion
Study: 29378515
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (BAT) - combination of educational classes, sham cognitive training, and balanced and tone exercises
Study: 25784665
Drug: GLP-1 (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (1.2 pmol/kg/min) during hyperglycemia (∼12 mmol/L)
Study: 31045821
Drug: Propofol total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol total intravenous anesthesia (TIVA)
Study: 18254806
Drug: Folic acid-
Normalized name: Folic acid-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid- and creatine-containing formulation
Study: 14751338
Drug: Mepartricin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin (40 mg daily)
Study: 9555600
Drug: Triazolam (0.1875,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.1875, 0.375, and 0.5625 mg)
Study: 7912819
Drug: Amisulpride (AMI)
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amisulpride (AMI) 50 mg for 2 weeks, then 100 mg for 4 weeks
Study: 21719636
Drug: Traditional infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional infant physical therapy (TIP)
Study: 16395750
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone with rapid tapering (medrol dose-pack)
Study: 16395750
Drug: Triamcinolone 100
Normalized name: TRIAMCINOLONE 100MCG 240D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone 100 mg, given intramuscularly
Study: 15684846
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment consisting of aromatherapy, footsoak, and reflexology
Study: 9414079
Drug: Carbohydrate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate meal three hours before exercise and a carbohydrate‐electrolyte solution during exercise (M + C)
Study: 9414079
Drug: Carbohydrate‐electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte solution during exercise (P + C)
Study: 8119423
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of betamethasone (Betnesol, Glaxo)
Study: 3311690
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of famotidine
Study: 17088002
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablets
Study: 8606262
Drug: Placebo (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (heparin and aspirin only)
Study: 25403522
Drug: Standard constipation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard constipation treatment options
Study: 26830074
Drug: Oral agents
Normalized name: DENTAL AND ORAL AGENTS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agents
Study: 10617985
Drug: Algae-produced high-DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algae-produced high-DHA triacylglycerol (170-260 mg/d)
Study: 7759034
Drug: hydroxyethylsalicyclate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyethylsalicyclate gel
Study: 2182448
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral verapamil treatment
Study: 11694805
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 microg)
Study: 11422131
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 800 microg/daily for 6 months
Study: 2566338
Drug: U.S. manufactured
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.S. manufactured 50 mg film coated, waxed tablets
Study: 2566338
Drug: European 50
Normalized name: European blueberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: European 50 mg film coated, waxed tablets
Study: 2566338
Drug: Oral reference
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral reference solution of almitrine bismesylate (0.5% w/v)
Study: 2566338
Drug: U.S. manufactured
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.S. manufactured tablets vs. European tablets
Study: 15167852
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine
Study: 7717643
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac
Study: 1907675
Drug: 45% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45% BCAA solution
Study: 8471652
Drug: Standard AA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AA solution (control group)
Study: 26458517
Drug: Interfering force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interfering force field B (treatment group)
Study: 9040722
Drug: Cabergoline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.25 to 4 mg/d)
Study: 9040722
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 to 600 mg/d)